Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO 2026 | Survival maturity of perioperative and adjuvant checkpoint inhibitor approvals

Name: Survival maturity of perioperative and adjuvant checkpoint inhibitor approvals
Uploaded: 2026-10-24T00:00:00Z
Duration: 1 min 41 s

Abhenil Mittal • 24 Oct 2026

ESMO 2026

General Antibodies Checkpoint Inhibitors

NIAGARA

Abhenil Mittal, MBBS, NOSM University, Sudbury, Canada, discusses a systematic review of ten Phase III trials that led to US Food and Drug Administration (FDA) approvals of perioperative, neoadjuvant and adjuvant immune checkpoint inhibitors across solid tumors. Most approvals relied on immature overall survival data, yet many received the highest-level guideline recommendations, highlighting a gap between the robustness of evidence and the strength of a recommendation. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.